Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm
Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm
复制标题
DOI：
10.1517/13543780902845622
复制
发表时间：
2009-04-01
影响因子：
6.1
通讯作者：
Merajver, Sofia
中科院分区：
文献类型：
--
作者：
Khan, Gazala;Merajver, Sofia
背景：四硫代钼酸盐（TM）是一种新型的抗肿瘤和抗血管生成剂，其作用机制是通过铜螯合和NF-κ B抑制。目的：本文综述了TM作为抗癌药物在人体研究中的科学原理。方法：对TM在癌症中的应用进行了系统的文献综述，包括临床前、动物和人体研究。本次检索的结果总结在本综述中。结果/结论：使用TM的铜螯合已在临床前和动物模型中证明了作为替代和新型抗血管生成剂的功效。使用TM在实体瘤中进行的I期和11项临床试验已经证明了疗效和有利的毒性特征。在癌症化学预防环境中使用铜降低作为抗血管生成策略仍有待研究。
Background: Tetrathiomolybdate (TM) is a novel anticancer and anti-angiogenic agent, which acts through copper chelation and NF-kappa B inhibition. Objective: This review summarizes the scientific rationale for the use of TM as an anticancer agent in human studies. Methods: A systematic review of the literature was conducted for the use of TM in cancer including preclinical, animal and human studies. The results of this search are summarized in this review. Results/conclusions: Copper chelation using TM has demonstrated efficacy in preclinical and animal models as an alternative and novel anti-angiogenic agent. Phase I and 11 clinical trials conducted in solid tumors using TM have demonstrated efficacy with favorable toxicity profile. The use of copper lowering as an anti-angiogenic strategy in the cancer chemopreventative setting remains to be investigated.